Peter Harwin. Mr. Harwin has served as a member of the board of directors of the Company since the Merger Closing and of Pre -Merger Oruka from February 2024 through the Merger Closing. Mr. Harwin is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co -founded in April 2016. Prior to Fairmount Funds Management, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE), Crescent Biopharma, Inc. (Nasdaq: CBIO), Damora Therapeutics, Inc. (Nasdaq: DMRA) and Paragon Therapeutics. Mr. Harwin served as a member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) from October 2020 to March 2025. Mr. Harwin received a B.B.A. from Emory University. We believe Mr. Harwin is qualified to serve as a member of the Board because of his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.